|
Published by: BizAcumen, Inc.
Published: Nov. 1, 2009 - 149 Pages
Table of Contents
- 1. METHODOLOGY
- Study Reliability and Reporting Limitations
- Disclaimers
- Quantitative Techniques & Reporting Level
- 2. GLOBAL MARKET OVERVIEW AND OUTLOOK
- Drug Delivery: A Quick Primer
- The Nose: An Attractive Avenue to Cross the Blood Brain Barrier
- Self-Administration of Drugs Brings Intranasal Drug Delivery Into the Spotlight
- Research & Technology Opens Up New Therapeutic Areas for Nasal Drug Delivery
- Recent Product Developments in the US Intranasal Drug Delivery Market (2007)
- R&D: Critical to the Commercialization of Intranasal Drug Delivery
- Tight Junction Biology: A Key Speed Breaker in Commercialization
- RNA Interference (RNAi): A Tool To Manipulate Tight Junctions
- Why Is Nasal Drug Delivery the Theme of All Drug Delivery Research Projects?
- Nasal Drug Delivery Devices & Equipments Preservative Free Systems (P.F.S.)
- Traditional Vs Advanced Intranasal Drug Delivery Devices
- Pitfalls Of Traditional Delivery Devices
- The Promise of New Advanced Delivery Devices
- Bi-Directional Nasal Drug Delivery: A Technology With a Huge Potential
- Benefits of Bi-Directional Delivery Authenticated Through Research Studies
- Market for Nasal Spray Devices in the US
- GSK Wields the Leadership Scepter in the US Intranasal Drugs Market
- The Batting Order
- 3. MARKET DYNAMICS
- Innovation in Drug Delivery: A Talisman for Success
- Controlled Release Technology is the Buzz Word
- Target-Specific Delivery Devices: Of Critical Value
- Safety & Cost: Primary Growth Drivers
- Preservatives Losing Sheen in Nasal Spray Formulations
- Multi-Dose Containers Evolve to Offer Resistance Against Microbial Contamination
- Bioavailability: An Important Facet of Intranasal Drug Delivery
- Chemical Modification
- Transient Modification & Limited Enzymatic Activity
- Bioavailability of Large Molecules
- Bio-Adhesive Polymers: Useful in Increasing Drug Absorption
- Mixed Opinions on Efficiency of Calcitonin Nasal Spray
- Nasal Preparations Gaining Foothold in Cough and Allergic Categories
- Patent Expiries Impact Market Opportunities
- 4. PRODUCT FACTS
- 5. RECENT TECHNOLOGICAL DEVELOPMENTS
- New-Generation Technologies and Devices
- ViaNase from Kurve Technology
- A New Product from OptiNose
- Nastech’s “Tight Junction Biology” Research Program
- ChiSys™ Nasal Delivery Technology from Archimedes
- 6. CORPORATE DEVELOPMENTS
- Zelos Therapeutics Collaborates with Aegis Therapeutics
- ImmuneRegen BioSciences Partners with LRRI
- Avamys™ Nasal Spray Receives Approval in Europe
- PMI-150 Receives Canadian Patent
- Nastech Enrolls 551 Patients for Phase 2 Trials of PYY3-36 Nasal Spray
- USFDA Approves FluMist® for Young Children
- USFDA Approves Veramyst Nasal Spray for Individuals Aged Two Years and Above
- Kurve Technology Inks Agreement with Schering-Plough
- MedImmune Clarifies FDA Observations
- FluMist(R) Receives FDA Approval for Refrigerated Formulation
- Nastech Regains Rights for PTH1-34 Nasal Spray
- NASONEX(R) Receives Ease-of-Use Commendation from Arthritis Foundation
- Aegis Therapeutics Establishes Cedar Therapeutics Inc.
- EMEA Provides Encouraging Feedback for Avamys™ Nasal Spray
- Kurve Technologies Introduces Blog on Nasal Drug Delivery
- Archimedes Pharma Commences Phase III Trials for NasalFent®
- Archimedes Presents New Clinical Data on NasalFent®
- LigoCyte Commences Clinical Trials for Intranasal Norovirus Vaccine
- Javelin Pharmaceuticals Reveals Phase 2 Study Results for PMI-100/150
- Javelin Pharmaceuticals Commences Phase III Studies for PMI-150
- Nastech Commences Phase 2 Trials for Insulin Nasal Spray
- ACAAI Reveals Results for Trials of Nasacort® AQ Nasal Spray in Children
- 7. MAJOR PLAYERS
- Aegis Therapeutics LLC (USA)
- Alza Corporation (USA)
- AptarGroup, Inc. (USA)
- Archimedes Pharma Limited. (UK)
- AstraZeneca Plc (UK)
- MedImmune, Inc. (USA)
- Bayer Consumer Care (USA)
- Bespak Plc (UK)
- GlaxoSmithKline Plc (UK)
- Intranasal Therapeutics, Inc. (USA)
- Javelin Pharmaceuticals, Inc (USA)
- Kurve Technology, Inc. (USA)
- MDRNA, Inc. (USA)
- Novartis AG (Switzerland)
- OptiNose AS (Norway)
- Pfizer, Inc. (USA)
- Rexam Plc (UK)
- Schering-Plough Corporation (USA)
- Sanofi-Aventis S.A. (France)
- Unigene Laboratories, Inc. (USA)
- 8. MARKET ANALYTICS
- Table 1: The US Nasal Drug Delivery Market: Sales Of Top Six Nasal Formulations for The Year 2005 (In US$ Million)
- Table 2: Percentage Market Shares of Leading Intranasal Drug Delivery Players in the US - 2006
- Table 3: Percentage Shares of Intranasal Drugs Manufacturer Value in the US - 2012
- Table 4: Top 10 Nasal Sprays, Drops and Inhalers Brands Ranked by Dollar Sales Through Drug Stores in the US - 2008 (In US $ Million)
- Table 5: Top 10 Nasal Sprays, Drops and Inhalers Brands Ranked by Unit Sales through Drug Stores in the US - 2008 (In Thousand Units)
- Table 6: Top Five Nasal Sprays Ranked by Dollar Retail Sales in the US - 2008 (In US $ Million)
- Table 7: Projected Revenues for Intranasal Sexual Dysfunction Drugs in the US -2010, 2011 & 2012 (in US$ Million)
- Table 8: Intranasal Drug Delivery Market by Therapeutic Area in the US: 2007-2015 (Sales in US$ Million)
- Table 9: Percentage Breakdown of Intranasal Drug Delivery Market by Therapeutic Area in the US for the Years 2008 & 2012
- COMPANIES PROFILED
AbstractThe US intranasal drug delivery market is witnessing an expansion of therapeutic applications from the delivery of conventional local therapeutic drugs to the delivery of systemic therapeutic drugs. The future of the technology hinges onto the effective exploitation of the fact that the nose offers an en-route that bypasses the blood-brain barrier through the olfactory region. The market also stands enthused by the continuous research and development activities, which are gradually opening up opportunities in new therapeutic areas, such as, osteoporosis, pain management, vitamin B12 deficiency, smoking cessation, migraines, nocturnal enuresis, rheumatoid arthritis, sexual dysfunction, cancer therapy, insulin-dependent diabetes, and epilepsy.
These and other market data and trends are presented in "Intranasal Drug Delivery: US Market Trends & Analysis" by BizAcumen LLC. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports,
company profiles and country profiles from over 700 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
© MarketResearch.com 2012
|
